Baloch ZW, Asa SL, Barletta JA et al (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33:27–63

Article  PubMed  Google Scholar 

Cooper DS et al (2009) Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214

Article  PubMed  Google Scholar 

Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133

Article  PubMed  PubMed Central  Google Scholar 

National comprehensive cancer network clinical practice guidelines in oncology, Thyroid Carcinoma, version 2.2024

Schlumberger M, Tahara M, Wirth LJ et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621–630

Article  PubMed  Google Scholar 

Brose MS, Nutting CM, Jarzab B et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet 384:319–328

Article  CAS  Google Scholar 

Ito Y, Onoda N, Kudo T et al (2021) Sorafenib and lenvatinib treatment for metastasis/recurrence of radioactive iodine-refractory differentiated thyroid carcinoma. In Vivo 35:1057–1064

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim M, Jin M, Jeon MJ et al (2023) Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study. Thyroid 33:91–99

Article  PubMed  CAS  Google Scholar 

Kiyota N, Schlumberger M, Muro K et al (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106:1714–1721

Article  PubMed  PubMed Central  CAS  Google Scholar 

Robinson B, Schlumberger M, Wirth LJ et al (2016) Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab 101:4103–4109

Article  PubMed  PubMed Central  CAS  Google Scholar 

Matsuyama C, Enokida T, Ueda Y et al (2023) Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 13:1139659

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tahara M, Brose MS, Wirth LJ et al (2019) Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 106:61–68

Article  PubMed  CAS  Google Scholar 

Tahara M (2018) Management of recurrent or metastatic thyroid cancer. ESMO Open 3:e000359

Article  PubMed  PubMed Central  Google Scholar 

Filetti S, Durante C, Hartl DM et al (2022) ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 33:674–684

Article  PubMed  CAS  Google Scholar 

Brose MS, Panaseykin Y, Konda B et al (2022) A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 107:776–787

Article  PubMed  Google Scholar 

Ohno K, Shibata T, Ito KI (2022) Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. Cancer Sci 113:3193–3210

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ornstein MC, Wood L, Elson P et al (2017) Clinical effect of dose escalation after disease progression in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 15:e275–e280

Article  PubMed  Google Scholar 

Masaki C, Sugino K, Akaishi J et al (2022) Successful dose escalation of lenvatinib for thyroid cancer after disease progression. Endocrine 78:77–84

Article  PubMed  CAS  Google Scholar 

Cancer Genome Atlas Research N (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676–690

Article  Google Scholar 

Masaki C, Sugino K, Tanizawa Y et al (2023) Multikinase inhibitor treatment patterns for advanced thyroid cancer in japan: an administrative claims database study. Drugs Real World Outcomes 10:145–158

Article  PubMed  Google Scholar 

Mohammadi M, Jansen-Werkhoven TM, Ijzerman NS et al (2022) Dutch gastrointestinal stromal tumor (GIST) Registry data comparing sunitinib with imatinib dose escalation in second-line advanced non-KIT exon 9 mutated GIST patients. Target Oncol 17:627–634

Article  PubMed  PubMed Central  Google Scholar 

Brose MS, Robinson BG, Sherman SI et al (2022) Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial. Cancer 128:4203–4212

Article  PubMed  CAS  Google Scholar 

Higashiyama T, Sugino K, Hara H et al (2022) Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer 173:210–218

Article  PubMed  CAS  Google Scholar 

Goto H, Kiyota N, Otsuki N et al (2018) Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria. Auris Nasus Larynx 45:1249–1252

Article  PubMed  Google Scholar